



Expedeon AG mandates ODDO SEYDLER BANK AG as Designated Sponsor

Heidelberg, Germany and Cambridge, UK, 12 June 2019 – ODDO SEYDLER BANK AG will henceforth be the second Designated Sponsor of Expedeon AG's share (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard), as Expedeon announced today. ODDO SEYDLER BANK has been mandated to ensure continuous trading on XETRA®, thus improving the tradability of Expedeon shares for investors. The share has been listed on the Frankfurt Stock Exchange and XETRA®, the electronic trading platform of the Deutsche Börse AG, since 2000.

Dr. Heikki Lanckriet, CEO of Expedeon, said: "By mandating a second Designated Sponsor, we want to enhance the continual tradability of our shares. Thus, our shareholders can buy and sell more shares at its market-driven price. Liquidity attracts liquidity and we aim to sustainably reduce the share's volatility."

In the XETRA electronic trading system, Designated Sponsors provide additional liquidity by committing to enter binding bid and ask prices (so-called quotes) in the order book therefore generating continuous trading in the respective shares. This task will be taken on by ODDO SEYDLER BANK for Expedeon's share. In its role of liquidity provision, Designated Sponsors must fulfil high-quality criteria (minimum requirements) set out by Deutsche Börse. ODDO SEYDLER BANK has achieved and continually maintained the highest rating by Deutsche Börse ("AA") since many years.

For further information, please contact:

Expedeon AG

Dr. Heikki Lanckriet
CEO/CSO

Phone: +44 1223 873 364

Email: heikki.lanckriet@expedeon.com

Investor website: www.investors.expedeon.com

MC Services AG (Investor Relations and International Media Relations)

Raimund Gabriel
Managing Partner

Phone: +49 89 210228 0

Email: expedeon@mc-services.eu

About Expedeon AG: www.expedeon.com

Expedeon is an enabler of exciting advances in medical science and patient care. The Company's core technologies, innovative products and services are used in research laboratories around the world, enabling scientists to push the boundaries of research and product development, and play an integral part in new diagnostic tools being brought to market. With applications spanning the entire workflows in genomics, proteomics and immunology, Expedeon's technologies both accelerate and simplify research and make new and cost-effective processes available to biopharmaceutical and diagnostic organisations alike, thereby underpinning its customers' development and commercialisation objectives. Expedeon's products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. Expedeon AG has offices in Germany, Spain, UK, USA and Singapore. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: EXN; ISIN: DE000A1RFM03).

About ODDO SEYDLER BANK AG

ODDO SEYDLER BANK AG is a merchant bank which is active in the capital markets primarily in three areas: market making as designated sponsor, fixed income trading and equities & fixed income specialist on the floor of the Frankfurt Stock Exchange. The bank supports medium-sized companies in all capital market-related projects and, in cooperation with its partner, FMR - Frankfurt Main Research AG, offers investors in the German-speaking area as well as internationally research with a focus on small and mid-caps in the DACH region.

This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of Expedeon AG may deviate greatly from the established conclusions or implied predictions contained in such statements. Expedeon does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.